Vikram R. Juneja
Takara (United States)(US)BioNTech (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, Diabetes and associated disorders
Most-Cited Works
- → In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target(2017)1,112 cited
- → PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity(2017)865 cited
- → Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity(2020)729 cited
- → Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth(2015)642 cited
- → Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade(2014)256 cited
- → PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance(2020)247 cited
- → Suppression by TFR cells leads to durable and selective inhibition of B cell effector function(2016)228 cited
- → Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity(2015)202 cited
- → Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells(2020)159 cited
- → Tracking Mesenchymal Stem Cells with Iron Oxide Nanoparticle Loaded Poly(lactide-co-glycolide) Microparticles(2012)143 cited